证券代码：002907 证券简称：华森制药 公告编号：2024-044 重庆华森制药股份有限公司 关于举行2024年半年度业绩网上说明会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重庆华森制药股份有限公司（以下简称 "公司"）《2024年半年度报告》全文 及其摘要将于2024年8月22日披露，为便于广大投资者更深入、全面地了解公司生产 经营情况和发展战略，公司拟召开"2024年半年度业绩说明会"。具体情况如下： 一、会议时间、地点 业绩说明会将于2024年8月27日（星期二）下午15:00～17:00通过网络会议的形 式在"路演中"平台举行。 二、参加人员 届时，公司董事长、独立董事、总经理、财务总监、董事会秘书等主要领导将 出席本次业绩网上说明会（如有特殊情况，参与人员会有调整）。 四、公开征集问题 为充分尊重投资者，广泛听取投资者的意见和建议，现就公司2024年半年度业 绩说明会提前向投资者公开征集问题，提问通道自发出公告之日起开放。投资者可 于2024年8月26日（星期一）17:00前将有关问题通过电子邮件的形式发送至公司投资 者关系邮箱（i ...

Financial Performance - The company's operating revenue for the first half of 2024 was ¥417,852,265.17, representing a 15.92% increase compared to ¥360,455,416.63 in the same period last year[12]. - Net profit attributable to shareholders for the first half of 2024 was ¥47,214,896.12, up 14.15% from ¥41,362,119.74 in the previous year[12]. - The net profit after deducting non-recurring gains and losses was ¥41,552,611.25, reflecting a 16.01% increase from ¥35,819,354.22 in the same period last year[12]. - The basic earnings per share for the first half of 2024 was ¥0.1131, an increase of 14.24% compared to ¥0.0990 in the previous year[12]. - The total assets at the end of the reporting period were ¥1,875,838,821.15, a 1.32% increase from ¥1,851,453,889.14 at the end of the previous year[12]. - The net assets attributable to shareholders at the end of the reporting period were ¥1,644,657,288.61, up 1.65% from ¥1,617,921,007.43 at the end of the previous year[12]. - The net cash flow from operating activities decreased by 57.81% to ¥64,757,981.71 from ¥153,499,879.95 in the same period last year[12]. - The company reported a total non-operating income of CNY 5,662,284.87, with a tax impact of CNY 996,667.94[16]. - The company achieved a revenue of 418 million CNY in the first half of 2024, representing a 15.92% increase compared to the same period last year[23]. - The net profit attributable to shareholders reached 47.21 million CNY, an increase of 14.15% year-on-year[23]. Research and Development - The company’s R&D investment amounted to 31.32 million CNY, accounting for 7.5% of total revenue[23]. - The company has established a PROTAC technology platform and is advancing one PROTAC small molecule innovation drug project[22]. - The company is focusing on the development of small molecule drugs in oncology, tumor immunology, and self-immunity diseases[22]. - The company has five clinical-stage innovative drugs in oncology, with potential indications covering tumor immunity and various solid tumors, and has filed 15 invention patents related to innovative drugs[25]. - The company completed 15 new patent applications, including 4 PCT applications, indicating a strong focus on innovation[23]. - The company has implemented a rigorous R&D plan and management system, optimizing cost structures to gain competitive advantages in the context of normalized centralized procurement[26]. Product Development and Market Expansion - The company has established the first special medical food production line in the Sichuan-Chongqing region and is currently developing special medical food products, with two projects expected to receive production approval by the end of 2024[18]. - The company launched 1 new drug and 8 new health consumer products during the reporting period, indicating a strong pipeline for future growth[18]. - Key products include five major products that have become leading items in their respective segments, contributing significantly to revenue[18]. - The company is expanding its product pipeline into oncology and metabolic disease areas, indicating a strategic shift towards high-demand therapeutic areas[18]. - The company has received drug registration certificates for several chemical generic drugs, including Methylsulfonylmethane and Fumaric Acid Vornorazone tablets[30]. - The company aims to launch new products such as Methylsulfonylmethane tablets and Compound Omeprazole Sodium Bicarbonate Capsules, focusing on market promotion[33]. Financial Management - The company reported a significant increase in tax expenses by 71.03% to ¥9,985,348.15, attributed to the increase in total profit and changes in deferred tax assets and liabilities[36]. - The company's financial expenses decreased by 44.11% to -¥7,457,282.35, primarily due to increased interest income[36]. - The company reported a financial expense of CNY -7,457,282.35, compared to CNY -5,174,743.96 in the previous year, indicating an increase in financial costs[117]. - The company’s cash and cash equivalents decreased to ¥297,753,191.04, representing 15.87% of total assets, down from 23.63% last year[42]. - The accounts receivable increased to ¥191,895,357.79, accounting for 10.23% of total assets, up from 9.15% last year[42]. - The company has increased its other current assets to ¥162,759,979.46, which is 8.68% of total assets, up from 2.71% last year[42]. Environmental Compliance - The company has obtained a pollutant discharge permit valid from August 4, 2021, to August 3, 2026[68]. - Wastewater discharge includes 3.8388 tons of COD and 0.034308 tons of NH3-N, both within the approved annual limits[69]. - The company has implemented a wastewater treatment process combining "dissolved air flotation + IC anaerobic + A/O" to ensure compliance before discharge[71]. - The company has achieved ISO14001 environmental management system certification, valid until December 9, 2026[74]. - The company has a dedicated environmental protection department and adheres strictly to national and local environmental laws[68]. - The company engages third-party services for wastewater treatment and environmental monitoring to ensure compliance[72]. Corporate Governance - The company emphasizes the importance of accurate and complete financial reporting, with all board members present for the meeting[2]. - Future plans and forward-looking statements do not constitute a commitment to investors, highlighting the need for caution regarding investment risks[2]. - The company held its annual general meeting on May 22, 2024, with an investor participation rate of 80%[63]. - The company has not implemented any employee stock ownership plans or other incentive measures during the reporting period[67]. - The company has not reported any major litigation or arbitration cases during the reporting period[78]. - The company has not engaged in any significant related-party transactions or non-operating fund occupation[77]. Shareholder Information - The total number of shares is 417,596,314, with 100% ownership[101]. - The company has 108,708,234 restricted shares, accounting for 26.03% of total shares[100]. - The company’s unrestricted shares amount to 308,888,080, representing 73.97% of total shares[100]. - The total number of ordinary shareholders at the end of the reporting period is 29,675[103]. - Chengdu Local Construction Machinery Co., Ltd. holds 45.04% of shares, totaling 188,100,000 shares[104]. - The shareholder You Hongtao holds 17.34% of shares, totaling 72,422,000 shares[104]. Strategic Partnerships - The company reported a strategic cooperation framework agreement with Beijing Zheyuan Technology Co., Ltd. on June 9, 2021, focusing on innovative drug development[93]. - The company has established a partnership with Chengdu Shangyi Information Technology Co., Ltd. for a cooperation agreement signed on June 18, 2021, with normal performance as of the report date[92]. - The company has engaged in a strategic cooperation framework agreement with Renfu Pharmaceutical Group Co., Ltd. on June 26, 2019, with normal performance as of the report date[94]. - The company has successfully negotiated a transaction with Epic Pharma, LLC for the transfer of ANDA approval and related technology for Dingluo Ketone tablets, with a transaction price of 1,383.86 thousand yuan[95]. Future Outlook - The company plans to continue focusing on market expansion and new product development to drive future growth[120]. - The company has outlined its future outlook and performance guidance in its half-year report, emphasizing growth strategies[93]. - The company plans to distribute a cash dividend of 0.35 yuan per 10 shares, totaling 14,615,870.99 yuan, which represents 100% of the total profit distribution[65].

证券代码：002907 证券简称：华森制药 公告编号：2024-040 重庆华森制药股份有限公司 第三届董事会第十三次会议决议公告 （一）审议通过《关于公司<2024 年半年度报告全文及其摘要>的议案》 表决情况：同意 9 票，反对 0 票，弃权 0 票。 表决结果：通过。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 （一）重庆华森制药股份有限公司（以下简称"公司"或"华森制药"）第三届 董事会第十三次会议（以下简称"本次会议"）通知以书面及电话方式于 2024 年 8 月 9 日向各位董事发出。 （二）本次会议于 2024 年 8 月 21 日上午 10:00 在公司三楼会议室以现场结 合通讯表决的方式召开。 （三）本次会议应到董事 9 名，实际出席并表决的董事 9 名。其中：董事游 洪涛、刘小英、王瑛、游雪丹、李嘉明、杜守颖、秦少容参加现场会议表决；董 事梁燕、游苑逸（Yuanyi You）以通讯表决方式出席会议。公司全体高级管理人 员列席会议。 （四）公司董事长游洪涛先生主持会议。 （五）本次会议的通知、召集和召开符合《中华人 ...

证券代码：002907 证券简称：华森制药 公告编号：2024-041 重庆华森制药股份有限公司 第三届监事会第九次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 （一）审议通过《关于公司<2024年半年度报告全文及其摘要>的议案》 表决情况：同意3票，反对0票，弃权0票 表决结果：通过 经审核，监事会认为董事会编制和审核公司《2024年半年度报告》的程序符 合法律、行政法规和中国证监会的规定，《2024年半年度报告》全文及其摘要内 容真实、准确、完整地反映了公司的实际情况，不存在任何虚假记载、误导性陈 述或者重大遗漏。 具体内容详见公司同日于《中国证券报》《上海证券报》《证券日报》《证 （一）重庆华森制药股份有限公司（以下简称"公司"或"华森制药"）第 三届监事会第九次会议（以下简称"本次会议"）通知以书面或电话方式于2024 年8月9日向全体监事发出。 （二）本次会议于2024年8月21日上午11：00时在公司三楼会议室以现场表 决的方式召开。 （三）本次会议应到监事3名，实际出席并表决的监事3名。 （四）公司监事会主 ...

证券代码：002907 证券简称：华森制药 公告编号：2024-043 重庆华森制药股份有限公司 关于质量回报双提升行动方案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 为践行以投资者为本的发展理念，增强投资者信心，促进公司长远健康可持 续发展，重庆华森制药股份有限公司（以下简称"公司"）以为全体股东创造持 续增长的价值为目标，围绕主责主业、公司治理、股东回报、投资者关系等方面， 制定了"质量回报双提升"行动方案。具体举措如下： 在创新药研发方面，公司推进创新药研发战略落地，专注于同类第一 （First-In-Class）与同类最佳（Best-In-Class）药物的开发，推进差异化研发管线， 并致力于打造具备国际视野的创新药研发团队，公司专注于肿瘤、肿瘤免疫以及 自勉性疾病领域的小分子药物开发，目前在研管线潜在适应症覆盖肿瘤免疫以及 肺癌、乳腺癌、结直肠癌、胰腺癌等多种实体瘤；在前沿技术布局方面，公司已 经开始建设 PROTAC 技术平台，且已推动 1 个 PROTAC 小分子创新药项目的研 发。 未来，公司将继续坚持以人才为公司基石，践行创新驱动 ...

证券代码：002907 证券简称：华森制药 公告编号：2024-042 重庆华森制药股份有限公司 关于2024年半年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 （一）董事会意见 1.公司第三届董事会第十次会议审议通过了《关于2024年中期分红安排的议案》， 根据法律法规、规范性文件及《公司章程》的有关规定，为进一步提高分红频次，增 强投资者回报水平，结合公司实际情况，对2024年中期分红的前提条件、金额上限及 分红程序做出了相关安排。经审议，董事会一致通过《关于2024年中期分红安排的议 案》。2024年5月22日，公司召开2023年年度股东大会审议通过了《关于2024年中期 分红安排的议案》，授权董事会根据股东大会决议在符合利润分配的条件下制定具体 的中期分红方案，本次利润分配预案无需提交股东大会审议。 2.公司第三届董事会第十三次会议审议通过了《关于公司<2024年半年度利润分 配预案>的议案》，经审议，公司董事会认为公司2024年半年度利润分配预案在保证 公司正常经营和长远发展的前提下，落实了《质量回报双提升行动方案》的精神，兼 ...

重庆华森制药股份有限公司 信息披露管理办法 第一章 总 则 第一条 为建立健全重庆华森制药股份有限公司（以下简称"公司"）信息 披露制度，规范公司信息披露义务人的信息披露行为，加强信息披露事务管理， 保护投资者合法权益，根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）、《深圳证券交易所股 票上市规则》（以下简称"《股票上市规则》"）、《上市公司信息披露管理办 法》、《深圳证券交易所上市公司自律监管指引第 5 号——信息披露事务管理》 以及《公司章程》等相关规定，结合公司实际情况，制定本办法。 第二条 本办法所称"信息披露"是指将可能对公司股票及其衍生品种交易 价格已经或可能产生较大影响、影响投资者决策而投资者尚未得知的信息，在规 定时间内、通过指定的媒体、以规定的方式向社会公众公布，并根据相关规定报 送上市地证券监管机构的行为。 第三条 信息披露文件包括定期报告、临时报告、招股说明书、募集说明书、 上市公告书、收购报告书等。 第四条 本办法适用于如下人员和机构： （一）公司董事会和监事会； 第二章 信息披露的基本原则 第五条 公司及相关信息披露义务人 ...

| 非经营性 | 资金占用方名称 | 占用方与上市 公司 | 上市公司核 算的会计科 | 2024 年期初占 | 2024 累计发生金额 | 上半年占用 | 2024 上半年占 用资金的利息 | 2024 上半年 偿还累计发 | 2024 上半 年期末占用 | 占用形成 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 资金占用 | | | | 用资金余额 | | | | | | 原因 | | | | | 的关联关系 | 目 | | （不含利息） | | （如有） | 生金额 | 资金余额 | | | | 控股股东、实际 | | | | | | | | | | | | | 控制人及其附属 | | | | | | | | | | | | | 企业 | | | | | | | | | | | | | 小计 | — | — | — | | | | | | | | — | | 前控股股东、实 | | | | | | | | | | | | | 际控制人及其附 | | | | | | | | | | ...

证券代码：002907 证券简称：华森制药 公告编号：2024-037 重庆华森制药股份有限公司 关于收到药品再注册批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重庆华森制药股份有限公司（以下简称"公司"）于近日收到重庆市药品监 督管理局（以下简称"市药监局"）核准签发的关于公司 1 个化学原料药的《化 学原料药再注册批准通知书》和 2 个药品的《药品再注册批准通知书》。现将相 关情况公告如下： 一、《再注册批准通知书》主要信息 | | | | | | （一）《化学原料药再注册批准通知书》主要信息 | | | --- | --- | --- | --- | --- | --- | --- | | 化 | 学 | 原 | 料 | 药 | 名 | 称 ： 盐酸戊乙奎醚 | | 英 | 文 | 名 | / | 拉 | 丁 | 名 ： Penehyclidine Hydrochloride | | 登 | | | 记 | | | 号 ： Y20170001628 | | 受 | | | 理 | | | 号 ：CYHZ2403768 渝 | | 通 ...

Financial Performance - In Q1 2024, the company achieved a revenue of 228 million CNY, a year-on-year increase of 21.78% due to strong growth in traditional Chinese medicine products, with the top five exclusive traditional Chinese medicines' revenue increasing by 34.61% [2] - The net profit attributable to shareholders was 40.35 million CNY, up 34.05% year-on-year, while the net profit excluding non-recurring items was 37.26 million CNY, an increase of 30.41% [2] - Basic earnings per share increased by 33.98% compared to the same period last year, driven by increased gross profit from core business revenue [3] Market Strategy and Product Development - The company is actively adjusting its product structure and increasing R&D investment to adapt to industry changes, aiming to create new performance growth points through innovative products [3] - The global market for specialized medical foods is approximately 3 billion USD, with China's market size around 7 billion CNY, indicating significant growth potential [4] - The company has established the first specialized medical food production base in the Sichuan-Chongqing region, expected to obtain its first production license by the end of 2024 [4] Supply Chain Management - To address rising costs of traditional Chinese medicine materials, the company conducts in-depth market research to ensure a stable supply chain and flexible procurement strategies [3] - The company employs a strategy of small-batch procurement to mitigate inventory risks and control costs, while continuously optimizing procurement cycles [3] Innovation and R&D - The company has five self-developed innovative drug projects in the oncology field, with ongoing patent applications and research progress aligning with expectations [5] - In 2023, the company applied for six innovative drug compound patents, with a total of 13 patents filed to date [5] Response to Market Challenges - The company acknowledges the significant impact of centralized procurement on existing products but sees limited effects on new products [5] - Strategies include exploring diversified development in advantageous areas, expanding market channels, and continuously launching new products to drive revenue growth [5] Sales Channels - The company's sales are primarily focused on public hospitals, with approximately 70% of sales occurring in this sector, while also expanding into e-commerce and new media channels [6]